bullishMarch 13, 2026 08:11 PMStock Analysis
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
SourceSeeking Alpha
Original Article AI Executive Summary
Capricor Therapeutics has received a new PDUFA date for its investigational product Deramiocel, leading analysts to upgrade the stock to a 'Buy' rating. This update is seen as a significant event that could enhance investor confidence in Capricor's potential product. The positive sentiment stems from the anticipation around the FDA's decision, which is critical for the company's future. Investors are now closely monitoring the progress as it could greatly affect stock performance. Overall, this news could boost Capricor's stock, provided the outcome is favorable.
Trader Insight
"Consider entering a long position in CAPR as the stock may see upward movement leading up to the PDUFA date, potentially benefiting from positive sentiment in the biotech sector."